Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Zolpidem is FDA-approved for the short-term treatment of insomnia characterized by difficulty with sleep initiation. The extended-release formulation (Ambien CR) is additionally approved for sleep maintenance insomnia (difficulty staying asleep). It is intended as short-term treatment — generally no more than 4 weeks — and should be combined with sleep hygiene education and behavioral interventions.

• Insomnia — sleep onset (immediate-release): difficulty falling asleep
• Insomnia — sleep maintenance (extended-release): difficulty falling and/or staying asleep
• Middle-of-the-night awakening (Intermezzo sublingual, lower-strength): for adults who cannot return to sleep after awakening, with at least 4 hours of planned sleep remaining

How It Works

Zolpidem is a positive allosteric modulator of GABA-A receptors — the primary inhibitory neurotransmitter receptors in the brain. It binds to the benzodiazepine site on GABA-A receptors, enhancing the effect of GABA (gamma-aminobutyric acid). When GABA binds to these receptors, chloride ions rush into the neuron, hyperpolarizing it and reducing neuronal firing.

Unlike benzodiazepines, which enhance GABA activity at all GABA-A receptor subtypes, zolpidem is relatively selective for receptors containing the alpha-1 subunit. Alpha-1-containing receptors are primarily responsible for sedation, amnesia, and anticonvulsant effects. Receptors with alpha-2, alpha-3, and alpha-5 subunits — responsible for anxiolytic, muscle relaxant, and cognitive effects — are less affected by zolpidem than by benzodiazepines.

This relative selectivity was initially thought to make zolpidem safer and with lower abuse potential than benzodiazepines. However, clinical experience has shown dependence, tolerance, withdrawal, and complex sleep behaviors still occur with meaningful frequency.

Side Effects

Common

• Drowsiness and next-day sedation (especially in women and older adults)
• Dizziness and lightheadedness
• Headache
• Anterograde amnesia — memory lapses for events occurring after taking the drug
• Gastrointestinal upset, nausea, diarrhea
• Drugged feeling or "hangover" the morning after

Serious

• Complex sleep behaviors — sleepwalking, sleep-driving, sleep-eating, and other activities performed while not fully awake and with no memory afterward; can result in serious injury or death (FDA black box warning)
• Next-day impaired driving — blood levels may remain high enough to impair driving, especially with the extended-release formulation and in women; the FDA requires the lowest effective dose, particularly for women
• Physical and psychological dependence — tolerance and withdrawal can develop even with prescribed use, especially beyond 4 weeks
• Rebound insomnia — insomnia worsens temporarily after stopping the drug
• Respiratory depression — primarily a concern in combination with other CNS depressants or in patients with sleep apnea
• Falls and fractures — especially in older adults; zolpidem significantly increases fall risk
• Hypersensitivity reactions — angioedema (swelling of the throat, tongue, face) reported; can be severe enough to impair breathing

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Opioids (oxycodone, hydrocodone, morphine)	Combined CNS depression increases risk of respiratory depression, sedation, coma, and death	High — FDA black box warning; avoid or use with extreme caution and monitoring
Benzodiazepines (alprazolam, lorazepam, diazepam)	Additive GABA-A enhancement; profound sedation and respiratory depression	High — avoid combination
Alcohol (ethanol)	Synergistic CNS depression; significantly increases sedation, memory impairment, and risk of complex sleep behaviors	High — absolute contraindication during zolpidem use
CYP3A4 inhibitors (ketoconazole, fluconazole, erythromycin)	Reduce zolpidem metabolism, substantially increasing blood levels and risk of adverse effects	Moderate to high — dose reduction may be needed
CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort)	Accelerate zolpidem metabolism, reducing its effectiveness	Moderate — may need alternative sleep agent
Antidepressants (SSRIs, SNRIs, TCAs)	Additive CNS depression; SSRIs may also increase complex sleep behavior risk	Moderate — monitor for excess sedation

Warnings & Contraindications

• Sex-based differences: Women metabolize zolpidem more slowly than men. The FDA has required that women be prescribed the lowest available strength of zolpidem due to higher next-morning blood levels and impaired driving risk.
• Elderly patients: Older adults are at substantially higher risk for falls, fractures, and confusion. Zolpidem is on the Beers Criteria list of medications potentially inappropriate for older adults. Non-pharmacologic treatments should be tried first.
• Depression: Zolpidem should be used with extreme caution in patients with depression, as it may worsen depressive symptoms and increases overdose risk due to CNS depression.
• Sleep apnea / respiratory disease: GABA-A agonists can worsen sleep-disordered breathing. Use is relatively contraindicated in patients with untreated sleep apnea or severe COPD.
• Substance use history: Patients with current or prior alcohol or drug misuse disorders are at higher risk of zolpidem misuse and dependence.
• Do not drive: Patients should not drive or operate heavy machinery the morning after taking zolpidem, especially with the extended-release formulation.

FAQ

Is zolpidem addictive?

Zolpidem carries a real risk of physical dependence and psychological addiction, particularly with prolonged use beyond 4 weeks, use of higher amounts, or use in patients with substance use history. Tolerance can develop, requiring higher amounts to achieve the same effect. Abrupt discontinuation after regular use can cause withdrawal symptoms including rebound insomnia, anxiety, tremors, and in severe cases, seizures. Tapering under medical supervision is recommended when stopping.

What are complex sleep behaviors and should I be worried?

Complex sleep behaviors are activities performed while in a mixed state of sleep and wakefulness — the person is not fully conscious and has no memory of the events afterward. These include sleepwalking, eating, making phone calls, having sex, and most dangerously, sleep-driving. These behaviors have caused serious injuries and deaths. The FDA issued a black box warning in 2019. If you or a family member notice any unusual nighttime activity, discontinue zolpidem immediately and contact your provider.

Why does zolpidem only work for short-term use?

Zolpidem's effectiveness for sleep typically diminishes over time due to tolerance development — the brain adapts to the presence of the drug, and the same amount produces less effect. Additionally, the underlying causes of chronic insomnia (anxiety, poor sleep habits, circadian disruption) are not addressed by the medication itself. Long-term sedative use can also worsen sleep architecture quality. CBT-I is proven effective for long-term insomnia management without these limitations.

Can I take zolpidem if I have sleep apnea?

Zolpidem causes respiratory depression by enhancing GABA-mediated inhibition in the brainstem. In patients with sleep apnea — who already have compromised airway patency and breathing during sleep — this can be particularly dangerous, potentially worsening apnea events and oxygen desaturation. Untreated sleep apnea is generally considered a relative contraindication. If you suspect sleep apnea, seek evaluation before using zolpidem or similar sedatives.

→ Sleep Aid Side Effects Guide → Insomnia Medications Guide